References
1. Zang, Y. and J.J. Lee, Adaptive clinical trial designs in oncology. Chin Clin Oncol, 2014. 3 (4).
2. Berry, S.M., et al., Bayesian adaptive methods for clinical trials . 2010: CRC press.
3. Bauer, P.J.B.u.I.i.M.u.B., Multistage testing with adaptive designs. 1989. 20 (4): p. 130-148.
4. EMEA, C.f.M.P.f.H.U.J.L., Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design.2007.
5. Food, U.F. Drug Administration %J Washington DC, and D. Administration, Guidance for industry: adaptive design clinical trials for drugs and biologics. 2010.
6. Elsäßer, A., et al., Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials, 2014. 15 : p. 383.
7. Chow, S.-C. and M. Chang, Adaptive design methods in clinical trials . 2006: Chapman and Hall/CRC.
8. Chow, S.C. and Y.H. Tu, On Two-stage Seamless Adaptive Design in Clinical Trials. J Formos Med Assoc, 2008. 107 (12 Suppl): p. 52-60.
9. Fedorov, V.V. and T.J.W.e.o.c.t. Liu, Enrichment design . 2007, Hoboken: John Wiley & Sons, Inc. p. 1-8.
10. Food and D. Administration, FDA Modernizes Clinical Trials With Master Protocols, 2019, CDER SBIA Chronicles .
11. Januskiene, J., et al., What are the patients’ and health care professionals’ understanding and behaviors towards adverse drug reaction reporting and additional monitoring? Pharmacoepidemiol Drug Saf, 2021.30 (3): p. 334-341.
12. Hazell, L. and S.A. Shakir, Under-reporting of adverse drug reactions : a systematic review. Drug Saf, 2006. 29 (5): p. 385-96.
13. Santoro, A., et al., Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works. Drug Saf, 2017.40 (10): p. 855-869.
14. Agency, E.M., Guideline on Good Pharmacovigilance Practices (GVP) Module X—Additional Monitoring. 2012.
15. Borg, J.-J., et al., Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? 2011.34 (3): p. 187-197.
16. Mammì, M., et al., Pharmacovigilance in pharmaceutical companies: An overview. 2013. 4 (1_suppl): p. S33-S37.
17. Kurzrock, R., et al., New drug approvals in oncology. Nat Rev Clin Oncol, 2020. 17 (3): p. 140-146.